Trim24 (Tif1a): An essential 'brake' for retinoic acid-induced transcription to prevent liver cancer

Cell Cycle

Volumn 7, Issue 23, 2008, Pages 3647-3652

  Khetchoumian, Konstantin ^a,b   Teletin, Marius ^a   Tisserand, Johan ^a   Herquel, Benjamin ^a   Ouararhni, Khalid ^a   Losson, Régine ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Hepatocarcinogenesis; Knockout; Mouse model; Proliferation; Quiescence; Retinoic acid receptor alpha; Transcriptional repression; TRIM24 TIF1

Indexed keywords

PROTEIN TRIM24; RETINOIC ACID; RETINOIC ACID RECEPTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG; NUCLEAR PROTEIN; RETINOIC ACID RECEPTOR ALPHA; TRANSCRIPTION FACTOR; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1;

CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; DRUG MECHANISM; HOMEOSTASIS; LIVER CELL; LIVER CELL CARCINOMA; NONHUMAN; PHENOTYPE; REVIEW; AGING; ANIMAL; ARTICLE; CYTOLOGY; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; LIVER TUMOR; METABOLISM; MOUSE; PATHOLOGY; POLYPLOIDY;

MUS;

AGING; ANIMALS; CELL PROLIFERATION; HEPATOCYTES; HOMEOSTASIS; LIVER NEOPLASMS; MICE; NUCLEAR PROTEINS; PHENOTYPE; POLYPLOIDY; RECEPTORS, RETINOIC ACID; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRETINOIN;

EID: 57349132931     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.23.7123     Document Type: Review

References (78)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127:27-34.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-76.
4. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31:339-46.
5. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6:674-87.
6. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48:20-37.
7. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental models of hepatocellular carcinoma. J Hepatol 2008; 48:858-79.
8. Lee JS, Grisham JW, Thorgeirsson SS. Comparative functional genomics for identifying models of human cancer. Carcinogenesis 2005; 26:1013-20.
9. Lévy L, Renard CA, Wei Y, Buendia MA. Genetic alterations and oncogenic pathways in hepatocellular carcinoma Ann N Y Acad Sci 2002; 963:21-36.
10. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006; 25:3778-86.
11. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27:55-76.
12. Coulouarn C, Gomez-Quiroz LE, Lee JS, Kaposi-Novak P, Conner EA, Goldina TA, Onishchenko GE, Factor VM, Thorgeirsson SS. Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology 2006; 44:1003-11.
13. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, Thorgeirsson SS. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004; 36:1306-11.
14. Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. Hepatology 2006; 43:145-50.
15. Miki T, Fleming TP, Crescenzi M, Molloy CJ, Blam SB, Reynolds SH, Aaronson SA. Development of a highly efficient expression cDNA cloning system: application to oncogene isolation. Proc Natl Acad Sci USA 1991; 88:5167-71.
16. Le Douarin B, Zechel C, Garnier JM, Lutz Y, Tora L, Pierrat P, Heery D, Gronemeyer H, Chambon P, Losson R. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J 1995; 14:2020-33.
17. Le Douarin B, Nielsen AL, garbier JM, Ichinose H, Jeanmougin F, Losson R, Chambon P. A possible involvement of TIF1α and TIF1β in the epigenetic control of transcription by nuclear receptors. EMBO J 1996; 15:6701-15.
18. vom Baur E, Zechel C, Heery D, Heine MJ, Garnier JM, Vivat V, Le Douarin B, Gronemeyer H, Chambon P, Losson R. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J 1996; 15:110-24.
19. Venturini L, You J, Stadler M, Galien R, Lallemand V, Koken MH, Mattei MG, Ganser A, Chambon P, Losson R, de Thé H. TIF1γ, a novel member of the transcriptional intermediary factor 1 family. Oncogene 1999; 18:1209-17.
20. Khetchoumian K, Teletin M, Mark M, Lerouge T, Cerviño M, Oulad-Abdelghani M, Chambon P, Losson R. TIF1δ, a novel HP1-interacting member of the transcriptional intermediary factor 1 (TIF1) family expressed by elongating spermatids. J Biol Chem 2004; 279:48329-41.
21. Beckstead R, Ortiz JA, Sanchez C, Prokopenko SN, Chambon P, Losson R, Bellen HJ. Bonus, a Drosophila homolog of TIF1 proteins, interacts with nuclear receptors and can inhibit bFTZ-F1-dependent transcription. Mol Cell 2001; 7:753-65.
22. Ransom DG, Bahary N, Niss K, Traver D, Burns C, Trede NS, Paffett-Lugassy N, Saganic WJ, Lim CA, Hersey C, Zhou Y, Barut BA, Lin S, Kingsley PD, Palis J, Orkin SH, Zon LI. The zebrafish moonshine gene encodes transcriptional intermediary factor 1γ, an essential regulator of hematopoiesis. PLoS Biol 2004; 2:237.
23. Cammas F, Mark M, Dollé P, Dierich A, Chambon P, Losson R. Mice lacking the transcriptional corepressor TIF1β are defective in early postimplantation development. Development 2000; 127:2955-63.
24. Weber P, Cammas F, Gerard C, Metzger D, Chambon P, Losson R, Mark M. Germ cell expression of the transcriptional co-repressor TIF1β is required for the maintenance of spermatogenesis in the mouse. Development 2002; 129:2329-37.
25. Cammas F, Herzog M, Lerouge T, Chambon P, Losson R. Association of the transcriptional corepressor TIF1β with heterochromatin protein 1 (HP1): an essential role for progression through differentiation. Genes Dev 2004; 18:2147-60.
26. He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, Massagué J. Hematopoiesis controlled by distinct TIF1g and Smad4 branches of the TGFβ pathway. Cell 2006; 125:929-41.
27. Dupont S, Zacchigna L, Cordenonsi M, Soligo S, Adorno M, Rugge M, Piccolo S. Germlayer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell 2005; 121:87-99.
28. Khetchoumian K, Teletin M, Tisserand J, Mark M, Herquel B, Ignat M, Zucman-Rossi J, Cammas F, Lerouge T, Thibault C, Metzger D, Chambon P, Losson R. Loss of Trim24 (Tif1α) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet 2007; 39:1500-6.
29. Wolf D, Goff SP. TRIM28 mediates primer binding site-targeted silencing of murine leukemia virus in embryonic cells. Cell 2007; 131:46-57.
30. Ignat M, Teletin M, Tisserand J, Khetchoumian K, Dennefeld C, Chambon P, Losson R, Mark M. Arterial calcifications and increased expression of vitamin D receptor targets in mice lacking TIF1α. Proc Natl Acad Sci USA 2008; 105:2598-603.
31. Kim J, Kaartinen V. Generation of mice with a conditional allele for Trim33. Genesis 2008; 46:329-33.
32. Nielsen AL, Ortiz JA, You J, Oulad-Abdelghani M, Khechumian R, Gansmuller A, Chambon P, Losson R. Interaction with members of the heterochromatin protein 1 (HP1) family and histone deacetylation are differentially involved in transcriptional silencing by members of the TIF1 family. EMBO J 1999; 18:6385-95.
33. Schultz DC, Friedman JR, Rauscher FJ, 3rd. Targeting histone deacetylase complexes via KRAB-zinc finger proteins: the PHD and bromodomains of KAP-1 form a cooperative unit that recruits a novel isoform of the Mi-2alpha subunit of NuRD. Genes Dev 2001; 15:428-43.
34. Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ, 3rd. SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev 2002; 16:919-32.
35. Sripathy SP, Stevens J, Schultz DC. The KAP1 corepressor functions to coordinate the assembly of de novo HP1-demarcated microenvironments of heterochromatin required for KRAB zinc finger protein-mediated transcriptional repression. Mol Cell Biol 2006; 26:8623-38.
36. Cammas F, Janoshazi A, Lerouge T, Losson R. Dynamic and selective interactions of the transcriptional corepressor TIF1β with the heterochromatin protein HP1 isotypes during cell differentiation. Differentiation 2007; 75:627-37.
37. Abrink M, Ortiz JA, Mark C, Sanchez C, Looman C, Hellman L, Chambon P, Losson R. Conserved interaction between distinct Krüppel-associated box domains and the transcriptional intermediary factor 1 β. Proc Natl Acad Sci USA 2001; 98:1422-6.
38. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9:138-41.
39. Niederreither K, Remboutsika E, Gansmuller A, Losson R, Dollé P. Expression of the transcriptional intermediary factor TIF1α during mouse development and in the reproductive organs. Mech Dev 1999; 88:111-7.
40. Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997; 278:1043-50.
41. Sherr CJ. Principles of tumor suppression. Cell 2004; 116:235-48.
42. Guidotti J-E, Brégerie O, Robert A, Debey P, Brechot C, Desdouets C. Liver cell polyploidization: a pivotal role for binuclear hepatocytes. J Biol Chem 2003; 21:19095-101.
43. Kudryavtsev BN, Kudryavtsev MV, Sakuta GA, Stein GI. Human hepatocyte polyploidization kinetics in the course of cell cycle. Virchows Arch B Cell Pathol Incl Mol Pathol 1993; 64:387-93.
44. Johnson JE. Age-related fine structural changes. In Aging and Cell Structure. Edited by Johnson JE Jr. New York: Plenum Press 1984; 2:37-88.
45. Storchova Z, Pellman D. From polyploidy to aneuploidy, genome instability and cancer. Nature Rev Mol Cell Biol 2004; 4:45-54.
46. Balmer JE, Blomhoff R. Gene expression regulation by retinoic acid. J Lipid Res 2002; 43:1773-808.
47. Ledda-Columbano GM, Pibiri M, Molotzu F, Cossu C, Sanna L, Sinbula G, Perra A, Columbano A. Induction of hepatocyte proliferation by retinoic acid. Carcinogenesis 2004; 25:2061-6.
48. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997; 386:761-3.
49. Tanaka S, Toh Y, Adachi E, Matsumata T, Mori R, Sugimachi K. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res 1993; 53:2884-7.
50. Park JY, Park WS, Nam SW, Kim SY, Lee SH, Yoo NJ, Lee JY, Park CK. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int 2005; 25:70-6.
51. Farazi PA, Glickman J, Horner J, Depinho RA. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res 2006; 66:4766-73.
52. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, Chen PJ, Hsiao TJ, Lee PH, Chen CJ. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000; 92:1159-64.
53. Cai RL, Meng W, Lu HY, Lin WY, Jiang F, Shen FM. Segregation analysis of hepatocellular carcinoma in a moderately high-incidence area of East China. World J Gastroenterol 2003; 9:2428-32.
54. Hemminki K, Li X. Familial liver and gall bladder cancer: a nationwide epidemiological study from Sweden. Gut 2003; 52:592-6.
55. Parada LA, Hallén M, Tranberg KG, Hägerstrand I, Bondeson L, Mitelman F, Johansson B. Frequent rearrangements of chromosomes 1, 7 and 8 in primary liver cancer. Genes Chromosomes Cancer 1998; 23:26-35.
56. Wong N, Lai P, Lee SW, Fan S, Pang E, Liew CT, Sheng Z, Lau JW and Johnson PJ. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size and cirrhosis. Am J Pathol 1999; 154:37-43.
57. Wong N, Lai P, Pang E, Leung TW, Lau JW, Johnson PJ. A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping. Hepatology 2000; 32:1060-8.
58. van Dekken H, Wink J, Alers JC, de Man RA, IJzermans JN, Zondervan PE. Genetic evaluation of the dysplasia-carcinoma sequence in chronic viral liver disease: a detailed analysis of two cases and a review of the literature. Acta Histochem 2003; 105:29-41.
59. Morazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008; 5:621-8.
60. Weiss B, Shannon K. Mouse cancer models as a platform for performing preclinical therapeutic trials. Curr Opin Genet Dev 2003; 13:84-9.
61. McCormick DL, Hollister JL, Bagg BJ, Long RE. Enhancement of murine hepatocarcinogenesis by all-trans retinoic acid and two synthetic retinamides. Carcinogenesis 1990; 11:1605-9.
62. Di Bisceglie AM, Osmack P, Brunt EM. Chemoprevention of hepatocellular carcinoma: use of tamoxifen in an animal model of hepatocarcinogenesis. J Lab Clin Med 2005; 145:134-8.
63. de Thé H, Marchio A, Tiollais P, Dejean A. A novel steroid thyroid hormone receptorrelated gene inappropriately expressed in human hepatocellular carcinoma. Nature 1987; 330:667-70.
64. Garcia M, de Thé H, Tiollais P, Samarut J, Dejean A. A hepatitis B virus pre-S-retinoic acid receptor β chimera transforms erythrocyte progenitor cells in vitro. Proc Natl Acad Sci USA 1993; 90:89-93.
65. Sano K, Takayama T, Murakami K, Saiki I, Makuuchi M. Overexpression of retinoic acid receptor alpha in hepatocellular carcinoma. Clin Cancer Res 2003; 9:3679-83.
66. Geubel AP, De Galocsy C, Alves N, Rahier J, Dive C. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology 1991; 100:1701-9.
67. Columbano A, Ledda-Columbano GM. Mitogenesis by ligands of nuclear receptors: an attractive model for the study of the molecular mechanisms implicated in liver growth. Cell Death Diff 2003; 10:19-21.
68. Shiota G, Tsuchiya H, Hoshikawa Y. The liver as a target organ of retinoids. Hepatol Res 2006; 36:248-54.
69. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1:181-93.
70. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002; 41:41-55.
71. Soprano DR, Qin P, Soprano KJ. Retinoic acid receptors and cancers. Annu Rev Nutr 2004; 24:201-21.
72. Okuno M, Kojima S, Matsushima-Nishiwaki R, Tsurui H, Muto Y, Fiedman SL, Moriwaki H. Retinoids in cancer chemoprevention. Current Cancer Drug Targets 2004; 4:285-98.
73. Mongan NP, Gudas LJ. Diverse actions of retinoid receptors in cancer prrevention and treatment. Differentiation 2007; 75:853-70.
74. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996; 334:1561-7.
75. Yasuda I, Shiratori Y, Adachi S, Obora A, Takemura M, Okuno M, Shidoji Y, Seishima M, Muto Y, Moriwaki H. Acyclic retinoid induces partial differentiation, downregulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J Hepatol 2002; 36:660-71.
76. Kagawa M, Sano T, Ishibashi N, Hashimoto M, Okuno M, Moriwaki H, Suzuki R, Kohno H, Tanaka T. An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGFa expression and cell proliferation. Carcinogenesis 2004; 25:979-85.
77. Sano T, Kagawa M, Okuno M, Ishibashi N, Hashimoto M, Yamamoto M, Suzuki R, Kohno H, Matsushima-Nishiwaki R, Takano Y, Tsurumi H, Kojima S, Friedman SL, Moriwaki H, Tanaka T. Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGFa-expressing oval-like cells and activated hepatic stellate cells. Nutr Cancer 2005; 51:197-206.
78. Yanagitani A, Yamada S, Yasui S, Shimomura T, Murai R, Murawaki Y, Hashiguchi K, Kanbe T, Saeki T, Ichiba M, Tanabe Y, Yoshida Y, Morino S, Kurimasa A, Usuda N, Yamazaki H, Kunisada T, Ito H, Murawaki Y, Shiota G. Retinoic acid receptor alpha dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology 2004; 40:366-75.